After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s | ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

With around 73 percent of Americans enjoying their daily coffee fix, it’s natural to wonder how your morning cup might ...

Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...

Eli Lilly (LLY) reported better-than-expected earnings for the second quarter on Thursday. But disappointing results of its much-awaited oral GLP-1 pill sent the stock down 13% in early trading. The ...

In the realm of innovative health solutions, the HonXi SMGT-GLP-1 Nano Microneedle Patch stands out as a revolutionary approach to managing weight and controlling blood sugar levels. As the prevalence ...

For the primary endpoint, orforglipron 36 mg, taken once per day without food and water restrictions, lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using ...

The trial randomized 559 participants across the U.S., China, India, Japan and Mexico in 1:1:1:1 ratio to receive either 3 mg, 12 mg or 36 mg orforglipron or placebo.